BTK and B-cell chronic lymphocytic leukemia: Similarly, LOXO-305 is an oral bioavailable selective non-covalent BTK inhibitor that can interrupt Cys481 mutated BTK, with responses in all CLL patients treated in a Phase I study, including one patient with disease harbouring the Cys481Ser mutation[182-184].